$230K
+$230K this year1 filing since 2026 · latest Options filed
Corami Biotech is a preclinical-stage cardiac biotechnology company based in Memphis, Tennessee, developing a platform for targeted delivery of therapeutics to the heart. Its approach uses a catheter-based device to place therapeutic gels directly on the surface of the heart, so treatment is localized to cardiac tissue rather than delivered systemically. The company's stated first indication is atrial fibrillation. It was incorporated in 2024 and is led by CEO Esra Roan, PhD, with founder Rebecca Levit, MD chairing the clinical advisory board.
What sets it apart
Localized, sustained delivery of therapeutics directly to the heart surface, aiming to give cardiac tissue a sustained dose while limiting the systemic side effects of conventional delivery.
A catheter-delivered platform that places therapeutic gels directly onto the surface of the heart for localized, sustained treatment of cardiac disease.
